World Library  
Flag as Inappropriate
Email this Article

AryoGen

Article Id: WHEBN0036746543
Reproduction Date:

Title: AryoGen  
Author: World Heritage Encyclopedia
Language: English
Subject: Science and technology in Iran, Biopharmaceuticals, Pharmaceutical companies of Iran, Industry of Iran
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

AryoGen

Aryogn Biopharma Co.
Type Private Company
Industry Pharmaceutical
Founded 2009
Headquarters Tehran, Iran
Area served Worldwide
Key people Dr. Behrouz Vaziri
Chairman & CEO
Products Pharmaceuticals, vaccines, over-the-counter medicines
Revenue Increase US$ 100 million
Employees Increase 1,000+ (2013)
Website AryoGen Pharmaceuticals

AryoGen Biopharma (in Persian: آریوژن زیست دارو ) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]

History

A group of scientific experts in a well experienced Biopharmaceutical company formed a totally new entity which started its production in 2010 with the name of AryoGen Biopharma. AryoGen was opened by Iranian president since its products is very crucial for community's health care system inside the country, in the region and around the world. AryoGen is the first company in the world, producing biosimilar form of Blood Coagulation Factor VII. For having this capability AryoGen has invested more than 50 million Euros in the production line. Also AryoGen has established production line for monoclonal antibodies which will stands among the list of 10 manufacturer of the world. These lines will start to industrial production early in the 2013.

Inside Aryogen, production line for AryoSeven
Inside Aryogen, production line for AryoSeven

Products

AryoGen's products include:

  • Blood Coagulation factor VII with the name of AryoSeven which is a biosimilar form of Novoseven with multi billion dollars world market and is used for hemophilia patients and other conditions
  • Altebrel with the generic name of Etanercept and original trade name of Enbrel which for some years was the no. one in the biopharmaceutical market and is used for treatment of autoimmune diseases
  • Zytux with the generic name of Rituximab and original trade name of Rituxan which is an anticancer biomedicine,
  • Hercease with the generic name of trastuzumab and original name of Herceptin which is a revolutionary drug in treatment of breast cancer
  • Arvestin with the generic name of bevacizumab and original trade name of Avestin and is used for treatment of some sort of cancer.

AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.

22000 sqm AryoGen Biopharma complex in a panorama photo
AryoGen Biopharma Complex.

See also

References

  1. ^ "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually.".  
  2. ^ World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
  3. ^ Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az

External links

  • AryoGen - Home
  • Hemophilia
  • List of biopharmaceutical companies
  • Launching domestic manufacture of anti-hemophilia drug
  • Related Clinical trials
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.